A recent study suggests that people who donate blood regularly may have genetic changes in their blood that could in fact reduce the risk of developing cancer. It is conducted by the researchers at the Francis Crick Institute, and the study has now provided new insights into how and why blood cancers develop. The study is published in the journal Blood and was conducted by the scientists from Heidelberg and the German Red Cross blood donation center. There is yet a need for further research to confirm these findings.

What Did The Study Find?

The researchers examined the blood of two groups of healthy male donors in their 60s:

• One group had donated blood three times a year for 40 years.
• The other group had donated only about five times in total.

The goal was to analyze genetic mutations in their blood and assess whether frequent donation had any impact on their genetic makeup.

How Can Blood Donation Affect Stem Cells?

As and when people age, their blood and other cells naturally develop mutations and some of them can also increase the risk of cancer. When anyone donates blood, his or her body compensates by producing new blood cells, which can influence the genetic diversity of stem cells in the bone marrow. The study also found that both groups had a similar number of mutations. For instance the frequent donors had 217 mutations, while the irregular donors had 212 mutations.

However, the nature of these mutations differed. In the frequent donors, 50% of the mutations were of a type not associated with a high risk of blood cancers, compared to only 30% in the irregular donors.

Further laboratory analysis showed that these specific mutations behaved differently from those linked to leukemia, a type of blood cancer. When human blood stem cells with these mutations were injected into mice, they were found to be highly effective at producing red blood cells, which is considered a positive outcome.

Dr. Hector Huerga Encabo, one of the study authors, emphasized that these mutations do not indicate an increased risk of leukemia. The findings suggest that regular blood donation may influence how stem cells evolve, but whether this translates into a lower cancer risk remains uncertain.

Read More: Who Can Donate Blood To Whom?

Limitations

One notable disadvantage is the "healthy-donor effect"—because blood donors are often healthier than the general population, their lower cancer risk could be unrelated to blood donation.

Dominique Bonnet, senior researcher and head of a stem-cell laboratory at the Francis Crick Institute, stressed the need for larger studies with female volunteers to confirm the findings.

Despite ongoing research into potential health benefits for donors, the primary goal of blood donation remains saving lives. NHS Blood and Transplant emphasized that while the study is interesting, further research is required to draw firm conclusions. The organization also noted that blood supplies are currently critically low and encouraged eligible individuals to donate.

Also Read: How Long After a Tattoo or Piercing Can I Donate Blood?

If you think that injections of botulinum toxin -- commonly known as Botox -- are only used to make skin wrinkle-free, you may be mistaken.

A new study led by US researchers has shown that Botox injections can act as a “rescue therapy” to treat conditions such as finger ulcers, digital ischemia, and gangrene that are difficult to manage with standard therapies.

Finger ulcers (or digital ulcers) are painful open sores, while acute digital ischemia causes the fingers to become extremely painful, cold, and sometimes pale or bluish in color. Gangrene is the dangerous death of body tissue (necrosis), often turning skin black, green, or purple.

These debilitating complications, often associated with conditions like lupus, rheumatoid arthritis, systemic sclerosis, or bacterial infections, are caused by reduced blood flow to the fingers and heal poorly.

Botox injections, which work by reducing blood vessel constriction and improving circulation, may help achieve complete healing of lesions in more than 85 percent of such patients, according to a study recently published in JAMA Dermatology.

“These new findings are particularly important because therapeutic options remain limited for the cutaneous and vascular manifestations of systemic sclerosis and other autoimmune diseases,” said Dr. Netchiporouk, a scientist in the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the McGill University Health Center.

Netchiporouk noted that the available vasodilator and immunosuppressive treatments are generally administered intravenously.

In contrast to Botox injections, these are also costly, minimally effective, and associated with significant adverse effects.

Also read: Botox Helped Her Burp: How Injectables Changed A 25-Year-Old's Life

The study also described the case of a 50-year-old man with a rare autoimmune disease that caused joint pain and digital necrosis (gangrene).

While traditional medications helped reduce his pain, he was forced to stop working, and the condition severely impacted his quality of life.

However, after receiving botulinum toxin injections, his pain was relieved, and sensation improved within 24 hours, and the necrosis began to improve within two weeks.

“This treatment has become an important tool, especially for patients with autoimmune vascular diseases that result in serious health consequences and for which there are few therapeutic options,” Netchiporouk said.

Also read: Why Regulatory Clarity Is Important for Safe Aesthetic Procedures in India

Botox: Safe, With Minimal Adverse Effects

The study, based on a systematic review and individual patient data meta-analysis of 30 published studies and one unpublished case involving 119 patients, found that only a few patients experienced adverse effects.

These were generally mild and short-lived, most commonly temporary muscle weakness or pain at the injection site.

“Our results show that botulinum toxin can improve blood circulation in the fingers and treat serious complications such as ulcers or gangrene, offering a safe and easy-to-administer alternative,” said Dr. Catherine Zhu, a dermatology resident at the McGill University Health Center.

Zhu added that the injections can be easily administered by rheumatologists and dermatologists in outpatient settings, reducing reliance on intravenous therapies that require hospitalization and increasing overall healthcare costs.

Importantly, in most cases, a single injection session was sufficient to achieve the desired response.

“Botulinum toxin can offer significant benefits with a favorable safety profile. It deserves further study to develop standardized protocols and optimize outcomes,” said Dr. Netchiporouk.

New Delhi: In a world where many are struggling with stress, work pressure, competition at school, and more, it does not come as a shocker that infertility has become too common. Couples often struggle to become parents, and that not only causes emotional stress but also takes a toll on relationships. But thanks to medical advancements, there are procedures like in vitro fertilisation (IVF) that make parenthood possible despite the many curveballs that infertility throws in the way. And with the precision that AI brings to the table, doctors have upped IVF success rates. But in some cases, even vitamin D deficiency can come in the way of a successful IVF treatment.

Read more: The Overlooked Role of Men in IVF: Why Their Silent Strength Is Key to Fertility Success

What is vitamin D deficiency?

Vitamin D, or the sunshine vitamin, is one of the most important nutrients that one needs for a healthy life. It influences mental health, bone and teeth strength, and, as it turns out, fertility as well. An extremely common occurrence in India, it is often seen in women of reproductive age. But can it also affect IVF success rates? Let's find out.

Dr. Kirti Singh, MBBS, MD, DNB (Obs & Gyn), Fellowship in Reproductive Medicine, Clinical Consultant, Aksigen IVF, interacted with Times Now Digital and explained how vitamin D affects women's health.

"Vitamin D is well known for maintaining calcium metabolism and bone health. Apart from that, emerging scientific evidence suggests that vitamin D may influence several pathways relevant to fertility, including ovarian function, endometrial receptivity, hormone regulation, and immune balance within the uterus. Vitamin D receptors (VDRs) are expressed in female reproductive tissues, including the ovaries, uterus, and placenta, hence having a significant impact on female fertility. Vitamin D supplementation has also been shown to have a positive effect on AMH expression. There are studies showing a positive correlation between follicular fluid (vitamin D levels) and fertilization rate. It is also known to regulate the expression of the HOXA10 gene, which helps in implantation," said Dr. Singh.

How does vitamin D deficiency affect fertility in women?

Dr. Nidhi Saluja, Centre Clinical Director, Indira IVF Hospital Limited, Gurugram, said, "Vitamin D deficiency is increasingly being recognised as an important consideration in female reproductive health, including in the context of assisted reproduction. Emerging clinical evidence suggests that low vitamin D is not merely an associated finding in infertility but a factor that may influence how ovaries function, how embryos implant, and how pregnancies progress. Since vitamin D receptors are present in reproductive tissues such as the ovaries, endometrium, and placenta, its role appears to extend beyond bone health into key aspects of fertility and reproductive support."

Read more: What Makes The IVF Journey So Hard On The Mind?

The expert went on to say that this becomes particularly relevant for women undergoing IVF, where factors such as ovarian function, embryo implantation, and endometrial receptivity are all important to treatment outcomes. Evidence suggests that women with sufficient vitamin D levels tend to show better implantation rates, improved embryo quality, and healthier endometrial receptivity. In clinical practice, low vitamin D is also often seen alongside diminished ovarian reserve and suboptimal ovarian response, especially in women already managing hormonal or metabolic challenges.

"Vitamin D status deserves greater attention as part of a comprehensive fertility assessment. While it should not be viewed as the sole determinant of IVF success, it may represent a potentially modifiable factor within broader fertility care. Identifying and addressing deficiency before conception or IVF can therefore help support a more informed and holistic treatment approach, particularly in women facing declining ovarian reserve or complex endocrine profiles," Dr. Saluja added.

What are the best sources of vitamin D?

Our main source of vitamin D, a fat-soluble steroid hormone, is sunlight. Only a small amount is obtained from our diet. In food, it is obtained from natural sources like eggs, fish, mushrooms, cod liver oil, green vegetables, yogurt, and milk. While vitamin D deficiency alone may not be the sole determinant of IVF success, studies increasingly indicate that correcting metabolic and nutritional imbalances can contribute to a healthier reproductive environment.

Even after being preventable and curable, tuberculosis (TB) retains its status as one of the deadliest infectious diseases more than 140 years after Robert Koch announced the discovery of Mycobacterium tuberculosis (Mtb) on March 24, 1882.

A major challenge is that millions of people carry it without knowing, and current tests often miss it. This is known as latent TB infection, where bacteria exist in an inactive state in the body.

While you do not feel sick, the infection can progress to active, contagious TB disease.

Ahead of World Tuberculosis Day, on March 24, scientists at the Indian Council of Medical Research-National Institute for Research in Tuberculosis (NIRT) in Chennai, reported developing an advanced blood test that can find TB even when it's hiding, and before it gets serious.

In the study, published in the Lancet journal eBioMedicine, the researchers explained about detecting circulating cell-free Mtb DNA in the plasma of individuals at high risk of developing TB disease via a dual target-based digital droplet PCR (ddPCR) assay.

The test was targeted at adults without a clear diagnosis of TB (asymptomatic or clinically diagnosed TB).

Using the test, the team led by Luke Elizabeth Hanna from NIRT's Department of Virology and Biotechnology, found TB in the blood up to 18 months before a person was diagnosed.

They identified eight out of 10 people at risk - all before they fell sick with the infectious disease.

“The new test performed better than all existing standard TB tests combined. This test could change how we fight TB - by finding it early, treating it faster, and stopping it from spreading,” said the team in the paper.

Tuberculosis: Advanced Blood Test

Detection of pathogen-derived cell-free DNA (cfDNA) has been gaining much attention in recent years for the diagnosis of several clinical conditions.

cfDNA is a liquid biopsy blood test that analyzes small, non-cellular DNA fragments circulating in the bloodstream.

The team found that the advanced blood test could find tiny traces of TB in the blood - even when a person feels completely healthy.

The test works by breaking a small blood sample into thousands of tiny droplets and searching each one for TB.

The study included 46 healthy household contacts of patients with pulmonary TB who developed TB within two years of follow-up, and 92 HHCs who did not progress to TB.

Plasma was obtained and subjected to testing using a ddPCR assay targeting two Mtb-specific insertion sequences, IS6110 and IS1081.

"Our findings support the diagnostic utility of ddPCR-based detection of circulating Mtb-derived cell-free DNA in plasma of individuals at high risk for progressing to active TB several months prior to clinical diagnosis," the ICMR-NIRT researchers said.

"These findings address important unmet diagnostic needs and indicate the potential of plasma-based Mtb ccfDNA detection to contribute to improved TB case detection and progress towards the WHO End TB goals," they added.

The WHO End TB Strategy

In 2024, an estimated 10.7 million people fell ill with TB worldwide, including 5.8 million men, 3.7 million women and 1.2 million children. TB is present in all countries and age groups, according to the World Health Organization (WHO).

The WHO aims to End TB by 2035, with a 95 percent reduction in deaths and a 90 percent reduction in incidence compared to 2015.